OPGN - OpGen, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

OpGen, Inc.

708 Quince Orchard Road
Suite 205
Gaithersburg, MD 20878
United States
301-869-9683
http://www.opgen.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full Time Employees59

Key Executives

NameTitlePayExercisedAge
Mr. Evan Jones M.B.A.316.54kN/A60
Mr. Timothy C. Dec323.46kN/A58
Mr. Vadim Sapiro330.88kN/A46
Dr. G. Terrance Walker Ph.D.N/AN/A58
Mr. Michael FarmerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company’s products include QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked in vitro diagnostic tests designed to identify antimicrobial resistant pathogens, as well as XpressFISH diagnostic test products for the identification of various infectious pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect the primary resistome profiles of gram negative organisms. OpGen, Inc. has a strategic collaboration with Hitachi High-Technologies Corporation to commercialize its genome mapping technology for mapping, assembly, and analysis of human DNA. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

OpGen, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.